Abstract
Nuclear medicine techniques play a fundamental role in the study of neuroendocrine tumours (NET) having the capability to image in vivo the amine pathway and the overexpression of the somatostatin receptors by means of specific radiopharmaceuticals designed for either scintigraphy or positron emission tomography-computed tomography (PET-CT). Meta-iodo-benzyl-guanidine (mIBG) and radiolabelled somatostatin analogues are the two main groups of radiopharmaceuticals available for planar scintigraphy and single photon emission computed tomography (SPECT) in NET imaging. In the present chapter the role of these imaging modalities is discussed, highlighting their advantages and limitations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wong KK, Waterfield RT, Marzola MC, et al. Contemporary nuclear medicine imaging of neuroendocrine tumours. Clin Radiol. 2012;67:1035–50.
van Essen M, Sundin A, Krenning EP, et al. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol. 2014;10:102–14. doi:10.1038/nrendo.2013.246.
Bombardieri E, Giammarile F, Aktolun C, et al. 131I/123I Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.
Bombardieri E, Ambrosini V, Aktolun C, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.
Pepe G, Bombardieri E, Lorenzoni A, Chiti A. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors. PET Clin. 2014;9(1):11–26.
Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-(18) F-fluorodopamine PET with I-123-metaiodobenzylguanidine and in-111-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613–9.
Fuccio C, Spinapolice EG, Chondrogiannis S, et al. Evolving role of SPECT/CT in neuroendocrine tumors management staging, treatment response, and follow-up. Clin Nucl Med. 2013;38(10):e384–9.
Fukuoka M, Taki J, Mochizuki T, et al. Comparison of diagnostic value of I-123 MIBG and high dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 2011;36:1–7.
Volterrani D, Orsini F, Chiacchio S, Bodei L. Multiagent targeting of neuroendocrine neoplasms. Clin Transl Imaging. 2013;1:407–21. doi:10.1007/s40336-013-0043-x.
Toumpanakis C, Kim MK, Rinke A, et al. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2014;99:63–74. doi:10.1159/000358727. Advanced Release: January 21, 2014.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Pepe, G., Kirienko, M. (2016). Radionuclide Imaging (SPECT). In: Ambrosini, V., Fanti, S. (eds) PET/CT in Neuroendocrine Tumors. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-29203-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-29203-8_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29202-1
Online ISBN: 978-3-319-29203-8
eBook Packages: MedicineMedicine (R0)